BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 25457974)

  • 21. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives.
    Joosten SC; Hamming L; Soetekouw PM; Aarts MJ; Veeck J; van Engeland M; Tjan-Heijnen VC
    Biochim Biophys Acta; 2015 Jan; 1855(1):1-16. PubMed ID: 25446042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma.
    Massari F; Ciccarese C; Santoni M; Lopez-Beltran A; Scarpelli M; Montironi R; Cheng L
    Expert Rev Anticancer Ther; 2015; 15(12):1367-9. PubMed ID: 26568023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
    Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
    Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.
    Kuusk T; Albiges L; Escudier B; Grivas N; Haanen J; Powles T; Bex A
    Angiogenesis; 2017 May; 20(2):205-215. PubMed ID: 28401381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NF-KappaB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues.
    Meteoglu I; Erdogdu IH; Meydan N; Erkus M; Barutca S
    J Exp Clin Cancer Res; 2008 Oct; 27(1):53. PubMed ID: 18928570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular endothelial growth factor as a biomarker for endostatin gene therapy.
    Braga MS; Turaça TL; Foguer K; Chaves KC; Pesquero JB; Chammas R; Schor N; Bellini MH
    Biomed Pharmacother; 2013 Jul; 67(6):511-5. PubMed ID: 23726969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".
    Alonso-Gordoa T; García-Bermejo ML; Grande E; Garrido P; Carrato A; Molina-Cerrillo J
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
    Hainsworth JD; Shipley DL; Reeves J; Arrowsmith ER; Barnes EK; Waterhouse DM
    Clin Genitourin Cancer; 2013 Sep; 11(3):283-289.e1. PubMed ID: 23684421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
    Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L
    Anticancer Res; 2001; 21(1B):777-9. PubMed ID: 11299843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Precision medicine for metastatic renal cell carcinoma.
    Sonpavde G; Choueiri TK
    Urol Oncol; 2014 Jan; 32(1):5-15. PubMed ID: 24239472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.
    Ljungberg BJ; Jacobsen J; Rudolfsson SH; Lindh G; Grankvist K; Rasmuson T
    BJU Int; 2006 Sep; 98(3):661-7. PubMed ID: 16925769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding the importance of smart drugs in renal cell carcinoma.
    Patard JJ; Rioux-Leclercq N; Fergelot P
    Eur Urol; 2006 Apr; 49(4):633-43. PubMed ID: 16481093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vascular endothelial growth inhibitor 174 is a negative regulator of aggressiveness and microvascular density in human clear cell renal cell carcinoma.
    Wu L; Li X; Ye L; Shayiremu D; Deng X; Zhang X; Jiang W; Yang Y; Gong K; Zhang N
    Anticancer Res; 2014 Feb; 34(2):715-22. PubMed ID: 24511004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The pathologist's role in the neoadjuvant strategy of renal-cell carcinoma].
    Leroy X; Edeline J; Rioux-Leclercq N
    Ann Pathol; 2011 Dec; 31(6):466-71. PubMed ID: 22172119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Biomarkers of response to molecular targeted therapy in renal cell carcinoma].
    Mizuno R; Oya M
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1088-91. PubMed ID: 21772092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
    Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
    Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Expression of COX-2 and VEGF and their correlation with angiogenesis in human clear cell renal cell carcinoma].
    Chang BD; Cao LS; Zhou HL
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):687-90. PubMed ID: 20021866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of response to targeted therapy in renal cell carcinoma.
    Eisengart LJ; MacVicar GR; Yang XJ
    Arch Pathol Lab Med; 2012 May; 136(5):490-5. PubMed ID: 22229848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy.
    Park JY; Lee JL; Baek S; Eo SH; Go H; Ro JY; Cho YM
    Hum Pathol; 2014 Jul; 45(7):1437-44. PubMed ID: 24784922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Renal cell carcinoma].
    Tomita Y
    Gan To Kagaku Ryoho; 2014 Feb; 41(2):172-7. PubMed ID: 24743196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.